
The utilization of total tumor volume (TTV) and whole-body mean standardized uptake value (SUVmean) on 177Lu-PSMA single-photon emission computed tomography/computed tomography (SPECT/CT; Lu-SPECT) can predict outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who are receiving 177Lu-PSMA therapy. As TTV is a lengthy process, researchers have examined the efficacy of utilizing an algorithm developed by deep learning to automatically generate TTV on Lu-SPECT.
A total of 95 177Lu-PSMA therapy SPECT/CT scans from 36 patients with mCRPC were gathered from the LuPIN trial, which analyzed the safety and efficacy of 177Lu-PSMA 617 and idronoxil (NOX66) in patients with end-stage mCRPC. Each patient was administered 1 to 6 cycles of therapy, with each cycle occurring every 6 weeks. The algorithm segmented all volumes of interest, with a 3-SUV threshold. The proposed method utilized CT-based, deep learning-generated normal organs for automatic removal of physiologic uptake on Lu-SPECT.
The average TTV for the proposed method was 927 mL compared with an average Gleason score (GS) TTV of 847 mL, which was not deemed significantly different (P=.054). The average absolute difference in TTV between the proposed method and GS was 110 mL.